Here the Investing News Network takes a look at the biggest Alzheimer’s disease treatment stocks on the NASDAQ. Companies are listed in order of market cap from largest to smallest, and all data was current as of June 19, 2024.
Market cap: US$32.56 billion; current share price: US$223.65
The first NASDAQ-listed Alzheimer’s drug company on this list is Massachusetts-based Biogen, a pioneer in the field of neuroscience. The firm is focused on developing, manufacturing and marketing therapies aimed at treating serious neurological, neurodegenerative, autoimmune and rare diseases.
Market cap: US$7.97 billion; current share price: US$75.48
Biopharma company Intra-Cellular Therapies is taking an intracellular approach to developing therapies for patients with complex psychiatric and neurologic diseases, including Parkinson’s disease and Alzheimer’s disease.
Market cap: US$7.63 billion; current share price: US$41.85
Neuroscience company Cerevel Therapeutics is focused on treating brain conditions such as Parkinson’s disease, Alzheimer’s disease psychosis, schizophrenia, epilepsy and panic disorder.
The firm’s drug candidate pipeline has five clinical-stage investigational therapies, including emraclidine for the treatment of both schizophrenia and Alzheimer’s disease psychosis.
This is an updated version of an article first published by the Investing News Network in 2019.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Leave a Reply